Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Experts Speculate On Cause Of Neurological Damage in French FAAH Inhibitor Study

This article was originally published in SRA

Executive Summary

The French expert committee set up to look at the preclinical data on Bial's FAAH inhibitor1, BIA 10-2474, says that the adverse events that led to the death of one volunteer and the hospitalization of several others in a Phase I study of the drug could be attributable either to an action of the compound beyond FAAH inhibition or to the effects exerted by a metabolite.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst